Coffee Consumption Not Found to Be Associated With Risk for Prostate Cancer
Post on January 18, 2017 by André Broussard, D.C.
January 17, 2017
International Journal of Cancer
TAKE-HOME MESSAGE
- There is ongoing controversy regarding the effects of coffee consumption on prostate cancer risk, with some clinical studies suggesting a protective effect. The authors used two genetic variants positively associated with caffeine consumption/metabolism as a proxy for coffee consumption. They found no association between these genetic variants and prostate cancer risk or mortality. There was, however, a slightly higher odds ratio of having nonlocalized prostate cancer (OR, 1.03).
- The authors identified no link between coffee consumption and prostate cancer risk. This study is limited by using genetic variants as a proxy for coffee consumption, which may not directly correlate with coffee consumption.
– Michael Johnson, MD
Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression.
Journal Abstract
Story Source